Clinical Trial: Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Brief Summary: Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

Detailed Summary:
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Current Primary Outcome: need of pulmonary surfactant [ Time Frame: one month ]

The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant


Original Primary Outcome: Same as current

Current Secondary Outcome: the incidence of bronchopulmonary dysplasia [ Time Frame: gestional age 36 weeks or later ]

the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.


Original Secondary Outcome: Same as current

Information By: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Dates:
Date Received: December 11, 2013
Date Started: January 2015
Date Completion:
Last Updated: February 10, 2015
Last Verified: December 2013